Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 27 2024 - 8:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2024 (Report No.3)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On February 27, 2024, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc-Clearmind Partnership Yields Three New International Patent
Applications for MDMA, Ibogaine and Ketamine Compounds.” A copy of this press release is furnished herewith as Exhibit 99.1 and
incorporated by reference herein.
The press release furnished
as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration
statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670, File
No. 333-255408, and File No. 333-275305) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: February 27, 2024 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and Chief Financial Officer |
3
Exhibit 99.1
SciSparc-Clearmind Partnership Yields Three New
International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:
SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of
therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration
with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery
and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind filed three patent
applications under the international Patent Cooperation Treaty (“PCT”).
The patent applications refer to novel proprietary compositions of
3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active
ingredient of SciSparc’s proprietary CannAmide™. These applications were previously filed as provisional patent applications with
the United States Patent and Trademark Office (“USPTO”).
As part of this collaboration, eight other applications have been filed
by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane
compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders. In addition, seven
applications were filed under the PCT.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning
of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For
example, SciSparc is using forward-looking statements when it discusses the Company’s ongoing collaboration with Clearmind. Historical
results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current
expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ
materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied
in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors”
in SciSparc’s Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and
Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024